What is the recommended NAD+ dosage?

NAD+ dosing varies by experience level. Beginners typically start at 100mg 2x/week, moderate users at 250mg 2x/week, and aggressive protocols use 500mg 3x/week.

How do you reconstitute NAD+?

NAD+ typically comes in 500mg vials. Add 5mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of NAD+?

The half-life of NAD+ is ~2-4 hours. This determines how frequently you need to dose for consistent blood levels.

NAD+

Anti-AgingInjectionResearchGrade B~2-4 hours half-life

Anti-AgingCellular EnergyNeuroprotectionDNA RepairMitochondrial Support8 weeks on / 2 weeks off

Benefits

Restores cellular energy production

Activates sirtuins (longevity pathways)

Supports DNA repair mechanisms

Boosts mental clarity and focus

Improves mitochondrial function

Half-Life

~2-4 hours

Route

Injection

Frequency

2x/week

Vial Sizes

500mg

BAC Water

5mL

Safety Grade

Grade B

Open NAD+ Dosage Calculator

Calculate exact syringe units for your vial and dose

About NAD+

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, essential for energy production, DNA repair, and cellular signaling. NAD+ levels decline up to 50% between ages 40-60, contributing to aging, fatigue, and cognitive decline. Injectable NAD+ bypasses the digestive system to restore cellular levels directly. It activates sirtuins (longevity genes) and supports mitochondrial function.

Who Should Consider NAD+

Adults over 40 experiencing age-related NAD+ decline and fatigue
Individuals seeking cognitive support and mental clarity
People in addiction recovery programs (NAD+ IV protocols)
Athletes wanting improved mitochondrial function and recovery
Patients with chronic fatigue or mitochondrial dysfunction
Adults interested in longevity and sirtuin activation

How NAD+ Works

NAD+ (Nicotinamide Adenine Dinucleotide) functions as a central metabolic coenzyme in over 500 enzymatic reactions. It exists in oxidized (NAD+) and reduced (NADH) forms, shuttling electrons in glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation to generate ATP. Beyond energy metabolism, NAD+ serves as a substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammation — SIRT1 and SIRT3 are particularly linked to longevity pathways. PARPs (poly-ADP-ribose polymerases) consume NAD+ to catalyze DNA damage repair; PARP1 activation after genotoxic stress can deplete cellular NAD+ pools rapidly. CD38, an NAD+-consuming ectoenzyme, increases with age and is now considered a primary driver of age-related NAD+ decline. Restoring NAD+ levels through direct IV or subcutaneous administration bypasses the multi-step conversion required by oral precursors (NMN, NR, niacin). Elevated NAD+ reactivates sirtuin-mediated deacetylation of PGC-1α, promoting mitochondrial biogenesis and improved oxidative capacity. It also supports the NAD+/NADH ratio in the electron transport chain, reducing electron leak and reactive oxygen species production.

What to Expect

Day 1-3

IV loading

Immediate increase in plasma NAD+ levels (up to 398% above baseline after 6-hour infusion). Some users report improved mental clarity and energy within hours. Nausea, flushing, or chest tightness may occur during infusion.

Weeks 1-2

SC maintenance

Transition to subcutaneous injections. Injection site stinging is common but manageable with slow administration. Early reports of improved sleep quality and reduced brain fog.

Weeks 3-6

Sustained energy improvements and better exercise recovery. Cognitive benefits become more consistent. Cellular NAD+ pools are being replenished through ongoing supplementation.

Weeks 7-12

Full benefits are realized including improved mitochondrial function, steady energy levels, and enhanced mental performance. Users in addiction recovery protocols often report reduced cravings at this stage.

Ongoing maintenance

Lower-frequency dosing (1-2x/week) to maintain elevated NAD+ levels. Periodic IV booster sessions every 1-3 months are used in some longevity protocols. Benefits are sustained with consistent use.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	100mg	2x/week
Moderate	250mg	2x/week
Aggressive	500mg	3x/week

Note: Cellular energy molecule. Doses shown in mcg: 100,000mcg = 100mg, 250,000mcg = 250mg, 500,000mcg = 500mg. Subcutaneous is better tolerated than IV. May sting on injection — inject slowly. Store reconstituted vial refrigerated.

How to Inject NAD+

Subcutaneous injection into abdominal fat or upper thigh. Inject slowly over 30-60 seconds to reduce stinging. Can also be administered IV over 2-6 hours in clinical settings. Rotate injection sites. Some users report less discomfort when the solution is warmed to room temperature before injection.

Cycling Protocol

On Period

8 weeks

Off Period

2 weeks

Some protocols run continuously at maintenance doses. Higher-dose IV protocols are typically done in short bursts (3-5 days). Subcutaneous dosing can be sustained longer with periodic breaks.

Pharmacokinetics

Half-Life

Bioavailability

IV: 100%; SC: not formally quantified but bypasses first-pass metabolism; Oral NAD+ has poor bioavailability

Tmax

~2-6 hours (IV infusion dependent on rate); SC: ~30-60 minutes

Data Confidence

low

Source: Estimated 2-4 hours based on IV infusion metabolome study showing rapid clearance and conversion to metabolites (PMID 31572171)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Injection site pain/stinging (inject slowly). Nausea, flushing, headache with IV administration. Subcutaneous is generally better tolerated.

Contraindications

Pregnancy or breastfeeding — no safety data available for injectable NAD+
Active cancer or history of malignancy — NAD+ may support rapidly dividing cells; effects on tumors not studied
Known hypersensitivity to NAD+ or nicotinamide derivatives
Severe cardiovascular disease — IV infusion may cause transient hemodynamic changes
Children and adolescents under 18 — not studied in pediatric populations

Drug Interactions

Chemotherapy agents — NAD+ may affect PARP inhibitor efficacy (e.g., olaparib, niraparib) by restoring NAD+ that PARPi drugs aim to deplete
Blood pressure medications — IV NAD+ may cause transient changes in heart rate and blood pressure; monitor closely
Immunosuppressants — NAD+ modulates inflammatory pathways via sirtuin activation; potential interaction with immunomodulatory drugs
Alcohol and sedatives — NAD+ is consumed during alcohol metabolism via alcohol dehydrogenase; concurrent heavy alcohol use may blunt therapeutic benefit
Diabetes medications — NAD+ influences glucose metabolism through SIRT1/AMPK pathways; monitor blood glucose when combining